| Literature DB >> 32910469 |
Sara De Biasi1, Domenico Lo Tartaro1, Marianna Meschiari2, Lara Gibellini1, Caterina Bellinazzi1, Rebecca Borella1, Lucia Fidanza1, Marco Mattioli1, Annamaria Paolini1, Licia Gozzi1, Dina Jaacoub2, Matteo Faltoni2, Sara Volpi2, Jovana Milić2, Marco Sita3, Mario Sarti4, Carlo Pucillo5, Massimo Girardis3, Giovanni Guaraldi2, Cristina Mussini2, Andrea Cossarizza1,6.
Abstract
Studies on the interactions between SARS-CoV-2 and humoral immunity are fundamental to elaborate effective therapies including vaccines. We used polychromatic flow cytometry, coupled with unsupervised data analysis and principal component analysis (PCA), to interrogate B cells in untreated patients with COVID-19 pneumonia. COVID-19 patients displayed normal plasma levels of the main immunoglobulin classes, of antibodies against common antigens or against antigens present in common vaccines. However, we found a decreased number of total and naïve B cells, along with decreased percentages and numbers of memory switched and unswitched B cells. On the contrary, IgM+ and IgM- plasmablasts were significantly increased. In vitro cell activation revealed that B lymphocytes showed a normal proliferation index and number of dividing cells per cycle. PCA indicated that B-cell number, naive and memory B cells but not plasmablasts clustered with patients who were discharged, while plasma IgM level, C-reactive protein, D-dimer, and SOFA score with those who died. In patients with pneumonia, the derangement of the B-cell compartment could be one of the causes of the immunological failure to control SARS-Cov2, have a relevant influence on several pathways, organs and systems, and must be considered to develop vaccine strategies.Entities:
Keywords: B cells; COVID‐19; Coronavirus; SARS‐CoV‐2; Uniform Manifold Approximation and Projection (UMAP); carboxyfluorescein succinimidyl ester CFSE; plasmablasts; principal component analysis (PCA); principal components (PCs)
Mesh:
Substances:
Year: 2020 PMID: 32910469 DOI: 10.1002/eji.202048838
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532